Security key
761330109
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)
CUSIP: 761330109
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 86,100
- Total 13F value
- $425,000
- Share change
- -80,984,685
- SEC-reported price per share
- $4.94
- Number of holders
- 1
- Value change
- -$246,196,147
- Number of sells
- 164
- Shares outstanding
- 104,661,494
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
1
Top holders
1
RVNC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Revance Therapeutics, Inc. SEC filings
Revance Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 761330109
Recent filing periods:
Ownership snapshot
Top reported holders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Teoxane SA
Disclosed value leader
Teoxane SA
Comparable rows
15/15
Latest evidence
30 Jan 2025
13D/G
13F
Lead comparable stake: 6.2%
13D/G row: Teoxane SA
Showing 1-6 of 15 holder rows.
Quick read
Teoxane SA leads the comparable SEC ownership view at 6.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Teoxane SA's linked filing trail.
Comparable ownership
Top 5
Teoxane SA
6.2%
FRANKLIN RESOURCES INC
4.6%
Palo Alto Investors LP
1.5%
BlackRock, Inc.
8.2%
Beryl Capital Management LLC
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Teoxane SA |
13D/G
|
6.2%
|
$32,335,404
6,550,800 shares
|
$0 | 30 Jan 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
4.6%
|
$23,617,550
4,784,658 shares
|
$0 | 30 Sep 2024 |
| Palo Alto Investors LP |
13D/G
Patrick Lee, MD
|
1.5%
|
$7,955,942
1,611,787 shares
|
$0 | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
8.2%
|
$26,136,151
8,597,418 shares
|
— | 31 Dec 2024 |
| Beryl Capital Management LLC |
13F
Company
|
5.7%
|
$18,042,427
5,935,009 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
5.4%
|
$17,100,277
5,625,091 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
86,100
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
169
Q1 2025 holders
1
Holder diff
-168
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend